SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 34; p. S168
Main Authors: Sangro, B., Chan, S., Kelley, R., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., De Toni, E., Furuse, J., Kang, Y., Galle, P., Rimassa, L., Heurgué, A., Tam, V., Dao, T., Thungappa, S., Breder, V., Ostapenko, Y., Reig, M., Makowsky, M., Gupta, C., Negro, A., Abou-Alfa, G.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-06-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1016/j.annonc.2023.04.487